Hydroxychloroquine shows promise for reducing some of the debilitating systems associated with primary progressive multiple sclerosis, a new study reports.
Coronavirus patients treated with chloroquine or hydroxychloroquine are significantly more likely to experience ventricular arrhythmias than those who were treated with other medications. The study also revealed that out of 100,000 COVID-19 patients who were hospitalized, the 15,000 who received hydroxychloroquine were more likely to have worse health outcomes than those treated with other drugs.
Researchers find no beneficial evidence to support the use of chloroquine or hydroxychloroquine, either used alone or in combination with azithromycin, for the treatment of COVID-19.
Study warns of the potentially serious adverse effects of prescribing hydroxychloroquine and azithromycin for the treatment of COVID-19. Some of the potential side effects include cardiac arrhythmias, hypoglycemia, and neuropsychiatric effects.
Hydroxychloroquine and azithromycin, two drugs touted as potential coronavirus therapeutics, could increase the risk of heart arrhythmias, cardiologists say.
